Abstract:The traditional chemotherapy, including Adriamycin (Doxorubicin, DOX), is widely used and is part of the first-line chemotherapy of invasive B cell lymphoma. DOX is nonselective cytotoxic drug and has many adverse effects, which limit its clinical application in combination with other anti-cancer drugs. Optimization of the delivery system targeting tumor microenvironment could be a feasible approach that may have significant clinical significance. Further, combination of DOX with other anticancer drugs, such as curcumin, can enhance the synergistic effects, possibly through epigenetic mechanisms. Hence, we evaluated the efficacy and toxicity of novel nanoparticles that enable the co-delivery of DOX and curcumin in the treatment of invasive B cell lymphoma both in vivo and vitro. The polymer nano materials [mPEG-b-P(Glu-co-Phe)] was used to co-load DOX and curcumin (CUR): L-DOX + CUR. DOX signal was measured to determine the ability of the drugs entering the cells by flow cytometry, and the different enrichment areas in the cells were directly observed by confocal microscope. The toxicity of LDOX + CUR was tested by CCK-8 assay in different cells, and the synergistic coefficients were calculated. The cell apoptosis and the possible mechanisms of apoptosis pathways regulation by L-DOX + CUR were examined using flow cytometry and Western Blot. The MTD (maximum tolerable dose) test was performed in mice. Tumor-bearing SCID mice (i.e., BJAB cell) were used to evaluate the in vivo efficacy of L-DOX + CUR. L-DOX + CUR, was prepared successfully, and the mole ratio of DOX and CUR fixed in 1.0:1.2. (DOX loading rate 9.7%, CUR loading rate 8.1%). L-DOX + CUR exhibited increased intracellular delivery and the main enrichment area of DOX was nucleus. L-DOX + CUR increased cytotoxicity, induced higher rates of apoptosis, and had synergistic effect, especially in BJAB cells (min CI 0.019). It even had epigenetic effect and affected miRNA levels favorably by down-regulating miR-21, miR-199a and up-regulating miR-98 and miR-200c. Additionally, L-DOX + CUR increased MTD in Kunming mice (i.e., 25 mg/kg), compared to DOX (10 mg/kg) and L-DOX (20 mg/kg). In BJAB cell bearing SCID mice, L-DOX + CUR treatment suppressed tumor growth compared to DOX or L-DOX alone, and exhibited less weight loss in mice. We developed new polymer nanoparticles-mPEG-b-P (Glu-co-Phe) co-loaded with DOX and DUR. L-DOX + CUR exhibited synergistic cytotoxic and apoptotic effects on invasive B cell lymphoma. Treatment of L-DOX + CUR potentiated tumor killing in xenografts and reduced toxicity in vivo.

Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates

Preparing Polymeric Microspheres with A Simplified Quality-By-Design Formulation Process for Sustained-Release Delivery of Native Protein Drugs

The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia

Stimuli-responsive Polymer-Doxorubicin Conjugate: Antitumor Mechanism and Potential As Nano-Prodrug.

Effect of Polymer Side Chains on Drug Delivery Properties for Cancer Therapy.

Polymer-lipid Hybrid Nanoparticles Synchronize Pharmacokinetics of Co-Encapsulated Doxorubicin-Mitomycin C and Enable Their Spatiotemporal Co-Delivery and Local Bioavailability in Breast Tumor.

A Comparison Study To Investigate The Effect Of The Drug-Loading Site On Its Delivery Efficacy Using Double Hydrophilic Block Copolymer-Based Prodrugs

A Tumor-Targeting Nano Doxorubicin Delivery System Built from Amphiphilic Polyrotaxane-Based Block Copolymers

Polymer-Doxorubicin Conjugate Micelles Based on Poly(Ethylene Glycol) and Poly(N-(2-Hydroxypropyl) Methacrylamide): Effect of Negative Charge and Molecular Weight on Biodistribution and Blood Clearance

Dual-acidity-labile polysaccharide-di-drugs conjugate for targeted cancer chemotherapy

Enzyme/pH-sensitive Polyhpma-Dox Conjugate As a Biocompatible and Efficient Anticancer Agent

Enhancing Cancer Targeting and Anticancer Activity by A Stimulus-Sensitive Multifunctional Polymer-Drug Conjugate

Optimization and characterization of Rituximab targeted multidrug loaded cyclodextrin nanoparticles against Non-Hodgkin Lymphoma

Development of Zwitterionic Polymer-Based Doxorubicin Conjugates: Tuning the Surface Charge to Prolong the Circulation and Reduce Toxicity.

Lymphoma immunochemotherapy: targeted delivery of doxorubicin via a dual functional nanocarrier.

Robust, Tumor-Homing and Redox-Sensitive Polymersomal Doxorubicin: A Superior Alternative to Doxil and Caelyx?

Redox-Sensitive Hyaluronic Acid Polymer Prodrug Nanoparticles for Enhancing Intracellular Drug Self-Delivery and Targeted Cancer Therapy

Reversibly Disulfide Cross-Linked Micelles Improve The Pharmacokinetics And Facilitate The Targeted, On-Demand Delivery Of Doxorubicin In The Treatment Of B-Cell Lymphoma

Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style.

Using N-(2-hydroxypropyl)methacrylamide Copolymer Drug Bioconjugate As a Novel Approach to Deliver a Bcl-2-targeting Compound HA14-1 in Vivo

Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy